Establishment Labs Holdings Inc.
ESTAHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeEstablishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa,. With a market capitalization of $2.72B, it sits in mid-cap territory. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Market Cap
$2.72B
Beta
1.07
P/E (TTM)
—
P/E (Fwd)
1234.40
EPS (TTM)
$-1.47
EPS (Fwd)
$0.07
ROE
-164.0%
ROA
-5.2%
Cash
$68.1M
Total Debt
$264.0M
Free CF
-$27.8M
52W Change
122.7%
Annual Financials
Cash vs Debt
On the balance sheet, ESTA has $68.1M in cash with $264.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$27.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -164.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $161.7M (2022) to $211.1M (2025), reflecting a 31% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Establishment Labs Holdings Inc. and its sector.